Characteristics, diagnosis and treatment of interdigitating dendritic cell sarcoma

Abstract

Abstract:Interdigitating dendritic cell sarcoma (IDCS) is a rare malignant tumor of the dendritic cell, derived from the hematopoietic tissue. The major clinical manifestation of IDCS is superficial lymphadenopathy, and the enlarged lymph nodes may appear in some atypical ereas, such as the lung, kidney, bladder and the pleura, etc. With the development of the pathological diagnosis and the application of immunohistochemical staining and electron microscopes, the case detection rate is apparently improved. With the high degree of malignant, rapid progress and poor prognosis of the disease, currently, surgical therapy is still the main approach to the treatment of IDCS.

Key words:Dendritic cell sarcoma, interdigitating,Diagnosis,Therapy

Li Junping, Zhao Rusen, Wang Yongtao, Li Bing, Zhang Guizhi. Characteristics, diagnosis and treatment of interdigitating dendritic cell sarcoma[J]. Journal of International Oncology, 2014, 41(8): 675-678.

References

［1］ Pileri SA, Grogan TM, Harris NL, et al. Tumours of Histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases［J］. Histopathol, 2002, 41(1): 1-29. ［2］ Kanaan H, AlMaghrabi J, Linjawi A, et al. Interdigitating dendritic cell sarcoma of the duodenum with rapidly fatal course: a case report and review of the literature［J］. Arch Pathol Lab Med, 2006, 130(2): 205-208. ［3］ Kadowaki N. The divergence and interplay between pDC and mDC in humans［J］. Front Biosci (Landmark Ed), 2009, 14: 808-817. ［4］ Feltkamp CA, Van Heerde P, FeltkampVroom TM, et al. A malignant tumor arising from interdigitating cells; light microscopical, ultrastructural, immunoand enzymehistochemical characteristics ［J］. Virchows Arch A Pathol Anat Histol, 1981, 393(2): 183-192. ［5］徐位顿, 王卓才. 左腋窝淋巴结指状突树突状细胞肉瘤1例［J］. 广东医学, 2002, 23: 682. ［6］ Zhang J, Liu B, Song N, et al. Interdigitating dendritic cell sarcoma presenting in the kidney combined with retroperitoneal leiomyosarcoma: a case report and literature review［J］. Oncol Lett, 2014, 7(2): 466-470. ［7］ Ye Z, Liu F, Cao Q, et al. Interdigitating dendritic cell sarcoma of lymph node mimicking granuloma: a case report and review of the literature［J］. Pol J Pathol, 2011, 62（4）: 274-277. ［8］ Perkins SM, Shinohara ET. Interdigitating and follicular dendritic cell sarcomas: a SEER analysis［J］. Am J Clin Oncol, 2013, 36(4): 395-398. ［9］ Kawachi K, Nakatani Y, Inayama Y, et al. Interdigital dentritie cell sarcoma of the spleen: report of a case with a review of the literature［J］. Am J Surg Pathol, 2002, 26（4）： 530-537. ［10］张哉根, 叶明福, 刁鑫伟, 等. 淋巴结指状突树突细胞肉瘤临床病理观察［J］. 诊断病理学杂志, 2005, 57(1): 87-89. ［11］ Jiang YZ, Dong NZ, Wu DP, et al. Interdigitating dendritic cell sarcoma presenting simultaneously with acute myelomonocytic leukemia: report of a rare case and literature review［J］. Int J Hematol, 2013, 97(5): 657-666. ［12］ Porter DW, Gupte GL, Brown RM, et al. Histiocytic sarcoma with interdigitating dendritic cell differentiation［J］. J Pediatr Hematol Oncol, 2004, 26(12): 827-830. ［13］ Barwell N, Howatson R, Jackson R, et al. Interdigitating dendritic cell sarcoma of salivary gland associated lymphoid tissue not associated with HHV8 or EBV infection［J］. J Clin Pathol, 2004, 57(1): 87-89. ［14］ Nayer H, Murphy KM, Hawkins AL, et al. Clonal cytogenetic abnormalities and BCL2 rearrangement in interdigitating dendritic cell sarcoma［J］. Leuk Lymphoma, 2006, 47(12): 2651-2654. ［15］ Wang HY, Li S, Woodford RL, et al. BCL2 chromosomal translocation is not a general feature of the interdigitating dendritic cell sarcoma［J］. Diagn Mol Pathol, 2010, 19(3): 169-171. ［16］ Radovi′c S, Dori′c M, Zujo H, et al. Interdigitating dendritic cell sarcoma of the liver and lung: a case report with morphohological and immunohistochemical features of tumor［J］. Bosn J Basic Med Sci, 2012, 12(3): 203-206. ［17］ Han HS, Lee OJ, Lim SN, et al. Extranodal interdigitating dendritic cell sarcoma presenting in the pleura: a case report［J］. J Korean Med Sci, 2011, 26(2): 304-307. ［18］ Parada D, Peńa KB, Gil I, et al. Interdigitating dendritic cell sarcoma presenting in the nasal region［J］. Pathol Res Pract, 2012, 208(6): 368-371. ［19］ Zhang J, Liu B, Song N, et al. Interdigitating dendritic cell sarcoma presenting in the kidney combined with retroperitoneal leiomyosarcoma: a case report and literature review［J］. Oncol Lett, 2014, 7(2): 466-470. ［20］ Zhou J, Zhou W, Bai C, et al. Interdigitating dendritic cell sarcoma: case report with review of the literature［J］. Onkologie, 2011, 34(11): 634-637. ［21］ Fonseca R, Yamakawa M, Nakamura S, et al. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review［J］. Am J Hematol, 1998, 59(2): 161-167. ［22］ Wu L, Liu YJ. Development of dendriticcell lineages［J］. Immunity, 2007, 26(6): 741-750. ［23］张秀茹, 陈桂秋, 于国, 等. 指状突树突细胞肉瘤2例临床病理观察［J］.诊断病理学杂志, 2010, 17(6): 431-434. ［24］吕翔, 王益华, 陈蕾, 等. 组织细胞肉瘤和树突细胞肿瘤的WHO分类介绍［J］. 临床与实验病理学杂志, 2005, 21(5): 525-528. ［25］ Wang H, Su Z, Hu Z, et al. Follicular dendritic cell sarcoma: a report of six cases and a review of the Chinese literature［J］. Diagn Pathol, 2010, 11(5): 67. ［26］ Sagransky MJ, Deng AC, Magro CM. Primary cutaneous langerhans cellsarcoma: a report of four cases and review of the literature［J］.Am J Dermatopathol, 2013, 35(2): 196-204. ［27］ Matushansky I, Charytonowicz E, Mills J, et al. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century［J］. Expert Rev Anticancer Ther, 2009, 9(8): 1135-1144. ［28］ De Pas T, Spitaleri G, Pruneri G, et al. Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases［J］. Crit Rev Oncol Hematol, 2008, 65(1): 1-7. ［29］ Olnes MJ, Nicol T, Duncan M, et al. Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy［J］. Leuk Lymphoma, 2002, 43(4): 817-821. ［30］ Lee SY, Lee SR, Chang WJ, et al. Successful treatment of disseminated interdigitating dendritic cell sarcoma with adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy［J］. Korean J Hematol, 2012, 47(2): 150-153. ［31］ Kairouz S, Hashash J, Kabbara W, et al. Dendritic cell neoplasms: an overview［J］. Am J Hematol, 2007, 82（10）: 924-928. ［32］ Azim HA, Elsedewy E, Azim HA. Imatinib in the treatment of follicular dendritic sarcoma：a report and review of literature［J］．Onkologie, 2007, 30(7): 381-384．［33］ Shukla N, Kobos R, Renaud T, et al. Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab［J］. Cancer, 2012, 118(15): 3719-3724. ［34］ Saygin C, Uzunaslan D, Ozguroglu M, et al. Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series［J］. Crit Rev Oncol Hematol, 2013, 88(2): 253-271. ［35］ Han SW, Kim ZS, Kim HM, et al. Interdigitating dendritic cell sarcoma occured alone in axilla［J］. J Korean Surg Soc, 2012, 82(5): 330-334. ［36］ De Pas T, Spitaleri G, Pruneri G, et al. Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases［J］. Crit Rev Oncol Hematol, 2008, 65(1): 1-7.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[6]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[7]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[8]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[9]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[10]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[11]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng.Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor[J]. Journal of International Oncology, 2024, 51(5): 298-302.
[12]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[13]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[14]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[15]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.